https://www.selleckchem.com/products/ha130.html
ia (30%, 0%, and 15%, respectively), mostly grade 1 or 2. Serious AEs were reported similarly across the 3 groups, and AEs leading to discontinuation were lower with LAP plus TRAS plus AI. Dual HER2 blockade with LAP plus TRAS plus AI showed superior PFS benefit versus TRAS plus AI in patients with HER2-positive/HR-positive MBC. This combination offers an effective and safe chemotherapy-sparing alternative treatment regimen for this patient population. Dual HER2 blockade with LAP plus TRAS plus AI showed superior PFS benefit versus TRAS p
Aimer
Commentaire
Partagez
